Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -40.77% is 13% below its 5-year average of -35.92%, near the low end of its 5-year range (-48.33%–-23.01%).
7.94% above its 12-month average of -44.28%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.27%.
RETURN ON ASSETS (ROA)
-40.77%
RETURN ON ASSETS (ROA) AVG TTM
-44.28%
RETURN ON ASSETS (ROA) AVG 3Y
-40.69%
RETURN ON ASSETS (ROA) AVG 5Y
-35.92%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+7.94%
CURRENT VS 3Y AVG
-0.21%
CURRENT VS 5Y AVG
-13.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-26.36%
vs the sector median at left
SOPHiA GENETICS S.A.
Market Cap
$619.15M
Return on Assets (ROA)
-40.77%
TTM Avg
-44.28%
3Y Avg
-40.69%
5Y Avg
-35.92%
Market Cap
$611.57M
Return on Assets (ROA)
-23.40%
TTM Avg
-34.85%
3Y Avg
-33.75%
5Y Avg
-41.05%
Market Cap
$630.63M
Return on Assets (ROA)
-15.25%
TTM Avg
-20.29%
3Y Avg
-14.84%
5Y Avg
-12.37%
Market Cap
$632.16M
Return on Assets (ROA)
-75.45%
TTM Avg
-62.27%
3Y Avg
-65.14%
5Y Avg
-53.59%
Market Cap
$634.30M
Return on Assets (ROA)
19.25%
TTM Avg
-15.00%
3Y Avg
-19.98%
5Y Avg
-33.37%
Market Cap
$638.20M
Return on Assets (ROA)
-37.63%
TTM Avg
-55.16%
3Y Avg
-41.63%
5Y Avg
-48.17%
Market Cap
$597.55M
Return on Assets (ROA)
45.55%
TTM Avg
3.15%
3Y Avg
-47.64%
5Y Avg
-20.78%
Market Cap
$596.01M
Return on Assets (ROA)
-13.75%
TTM Avg
-12.94%
3Y Avg
-23.44%
5Y Avg
-17.36%
Market Cap
$584.48M
Return on Assets (ROA)
-7.75%
TTM Avg
-4.25%
3Y Avg
-2.93%
5Y Avg
9.76%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SOPHiA GENETICS S.A. (SOPH) | $619.15M | -40.77% | -44.28% | -40.69% | -35.92% |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | -23.40% | -34.85% | -33.75% | -41.05% |
| OmniAb, Inc. (OABI)vs › | $630.63M | -15.25% | -20.29% | -14.84% | -12.37% |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -75.45% | -62.27% | -65.14% | -53.59% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 19.25% | -15.00% | -19.98% | -33.37% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | -37.63% | -55.16% | -41.63% | -48.17% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 45.55% | 3.15% | -47.64% | -20.78% |
| AngioDynamics, Inc. (ANGO)vs › | $596.01M | -13.75% | -12.94% | -23.44% | -17.36% |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | -7.75% | -4.25% | -2.93% | 9.76% |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | -7.77% | -7.89% | -5.07% | -5.95% |
ROA
-40.8%
ROE
-97.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -48.33% |
| 2024-12-31 | -40.24% |
| 2023-12-31 | -38.31% |
| 2022-12-31 | -35.86% |
| 2021-12-31 | -23.01% |
| 2020-12-31 | -29.78% |
| 2019-12-31 | -65.42% |
| 2018-12-31 | 0.00% |
